 | Up a level |
Weber, M S R; Duran Ramirez, J J; Hentzien, M; Cavassini, M; Bernasconi, E; Hofmann, E; Furrer, H; Kovari, H; Stöckle, M; Schmid, P; Haerry, D; Braun, D L; Günthard, H F; Kusejko, K (2024). Time Trends in Causes of Death in People with HIV: Insights from the Swiss HIV Cohort Study. (In Press). Clinical infectious diseases Oxford University Press 10.1093/cid/ciae014
Hovaguimian, F; Martin, E; Reinacher, M; Rasi, M; Schmidt, A J; Bernasconi, E; El Amari, E B; Braun, D L; Calmy, A; Darling, K; Christinet, V; Depmeier, C; Hauser, C; Läuchli, S; Notter, J; Stoeckle, M; Surial, B; Vernazza, P; Bruggmann, P; Tarr, P; ... (2022). Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection. HIV medicine, 23(2), pp. 146-158. Wiley 10.1111/hiv.13175
Kovari, H; Surial, B; Tarr, P E; Cavassini, M; Calmy, A; Schmid, P; Bernasconi, E; Rauch, A; Wandeler, G; Ledergerber, B (2021). Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study. HIV medicine, 22(7), pp. 623-628. Wiley 10.1111/hiv.13106
Reichmuth, M L; Chaudron, S E; Bachmann, N; Nguyen, H; Böni, J; Metzner, K J; Perreau, M; Klimkait, T; Yerly, S; Hirsch, H H; Hauser, C; Ramette, A; Vernazza, P; Cavassini, M; Bernasconi, E; Günthard, H F; Kusejko, K; Kouyos, R D (2021). Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission. HIV medicine, 22(5), pp. 346-359. Wiley 10.1111/hiv.13030
Hampel, B; Kusejko, K; Kouyos, R D; Böni, J; Flepp, M; Stöckle, M; Conen, A; Béguelin, C; Künzler-Heule, P; Nicca, D; Schmidt, A J; Nguyen, H; Delaloye, J; Rougemont, M; Bernasconi, E; Rauch, A; Günthard, H F; Braun, D L; Fehr, J (2020). Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017. HIV medicine, 21(4), pp. 228-239. Wiley 10.1111/hiv.12821
Kusejko, K; Marzel, A; Hampel, B; Bachmann, N; Nguyen, H; Fehr, J; Braun, D L; Battegay, M; Bernasconi, E; Calmy, A; Cavassini, M; Hoffmann, M; Böni, J; Yerly, S; Klimkait, T; Perreau, M; Rauch, Andri; Günthard, H F; Kouyos, R D (2018). Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland. HIV medicine, 19(10), pp. 688-697. Blackwell Science 10.1111/hiv.12660
Aebi-Popp, K; Wandeler, G; Salazar Vizcaya, L; Metzner, K; Stöckle, M; Cavassini, M; Hoffmann, M; Lüthi, A; Suter, F; Bernasconi, E; Fehr, J; Furrer, H; Rauch, A (2018). Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men. HIV medicine, 19(6), pp. 420-425. Blackwell Science 10.1111/hiv.12602
Marzel, A; Shilaih, M; Turk, T; Campbell, N K; Yang, W-L; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Furrer, Hansjakob; Calmy, A; Battegay, M; Cavassini, M; Bernasconi, E; Schmid, P; Metzner, K J; Günthard, H F; Kouyos, R D (2017). Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships. HIV medicine, 18(9), pp. 667-676. Blackwell Science 10.1111/hiv.12507
Gebreselassie, Hiwot Mamo; Kraus, David; Fux, C A; Haubitz, Sebastian; Scherrer, A; Hatz, C; Veit, O; Stoeckle, M; Fehr, J; de Lucia, S; Cavassini, M; Bernasconi, E; Schmid, P; Furrer, Hansjakob; Stähelin, Cornelia Johanna (2017). Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort Study. HIV medicine, 18(8), pp. 564-572. Blackwell Science 10.1111/hiv.12491
Hasse, Barbara; Tarr, Philip E; Marques-Vidal, Pedro; Waeber, Gerard; Preisig, Martin; Mooser, Vincent; Valeri, Fabio; Djalali, Sima; Rauch, Andri; Bernasconi, Enos; Calmy, Alexandra; Cavassini, Matthias; Vernazza, Pietro; Battegay, Manuel; Weber, Rainer; Senn, Oliver; Vollenweider, Peter; Ledergerber, Bruno; Aubert, V; Barth, J; ... (2015). Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. Open Forum Infectious Diseases, 2(3), ofv108. Oxford University Press 10.1093/ofid/ofv108
Aebi-Popp, Karoline; Kouyos, R; Bertisch, B; Stähelin, Cornelia Johanna; Rudin, C; Hoesli, I; Stoeckle, M; Bernasconi, E; Cavassini, M; Grawe, C; Lecompte, T D; Rickenbach, M; Thorne, C; Martinez de Tejada, B; Fehr, J (2015). Postnatal retention in HIV care: insight from the Swiss HIV Cohort Study over a 15-year observational period. HIV medicine, 17(4), pp. 280-288. Blackwell Science 10.1111/hiv.12299
Rosin, C; Elzi, L; Thurnheer Zürcher, Maria Christine; Fehr, J; Cavassini, M; Calmy, A; Schmid, P; Bernasconi, E; Battegay, M (2015). Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV Cohort Study. HIV medicine, 16(5), pp. 319-325. Blackwell Science 10.1111/hiv.12203
Kouyos, Roger D; Hasse, Barbara; Calmy, Alexandra; Cavassini, Matthias; Furrer, Hansjakob; Stöckle, Marcel; Vernazza, Pietro L; Bernasconi, Enos; Weber, Rainer; Günthard, Huldrych F; Aubert, V; Battegay, M; Bernasconi, E; Böni, J; Bucher, H C; Burton-Jeangros, C; Calmy, A; Cavassini, M; Dollenmaier, G; Egger, M; ... (2015). Increases in Condomless Sex in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2(2), ofv077. Oxford University Press 10.1093/ofid/ofv077
Weber, R; Huber, M; Battegay, M; Stähelin, Cornelia Johanna; Castro Batanjer, E; Calmy, A; Bregenzer, A; Bernasconi, E; Schoeni-Affolter, F; Ledergerber, B (2015). Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study. HIV medicine, 16(3), pp. 137-151. Blackwell Science 10.1111/hiv.12184
Clifford, G M; Lise, M; Franceschi, S; Egger, M; Bouchardy, C; Korol, D; Levi, F; Ess, S; Jundt, G; Wandeler, G; Fehr, J; Schmid, P; Battegay, M; Bernasconi, E; Cavassini, M; Calmy, A; Keiser, O; Schöni-Affolter, F; Swiss HIV Cohort Study, (2012). Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. British journal of cancer, 106(3), pp. 447-452. Basingstoke: Nature Publishing Group 10.1038/bjc.2011.558
Thierfelder, C; Weber, R; Elzi, L; Furrer, H; Cavassini, M; Calmy, A; Bernasconi, E; Gutmann, C; Ledergerber, B; Swiss HIV Cohort Study Group, (2012). Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study. HIV medicine, 13(2), pp. 118-26. Oxford: Blackwell Science 10.1111/j.1468-1293.2011.00949.x
Huber, M; Ledergerber, B; Sauter, R; Young, J; Fehr, J; Cusini, A; Battegay, M; Calmy, A; Orasch, C; Nicca, D; Bernasconi, E; Jaccard, R; Held, L; Weber, R; Swiss HIV Cohort Study Group, (2012). Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV medicine, 13(7), pp. 387-397. Oxford: Blackwell Science 10.1111/j.1468-1293.2011.00984.x
Weber, R; Ruppik, M; Rickenbach, M; Spoerri, A; Furrer, Hansjakob; Battegay, M; Cavassini, M; Calmy, A; Bernasconi, E; Schmid, P; Flepp, M; Kowalska, J; Ledergerber, B; Swiss HIV Cohort Study, (SHCS) (2012). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV medicine, 14(4), pp. 195-207. Oxford: Blackwell Science 10.1111/j.1468-1293.2012.01051.x
Magenta, L; Dell-Kuster, S; Richter, W O; Young, J; Hasse, B; Flepp, M; Hirschel, B; Vernazza, P; Evison, J; Cavassini, M; Decosterd, L A; Bucher, H C; Bernasconi, E; Swiss HIV Cohort Study (SHCS), (2011). Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy. AIDS research and human retroviruses, 27(5), pp. 525-33. New York, N.Y.: Mary Ann Liebert 10.1089/aid.2010.0207
Ledergerber, B; Cavassini, M; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B; Furrer, H; Rickenbach, M; Weber, R; Swiss HIV Cohort Study (SHCS), (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV medicine, 12(5), pp. 279-88. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00880.x
Young, J; Scherrer, A U; Günthard, Hf; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, Ca; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, Hc; Swiss HIV Cohort Study, (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV medicine, 12(5), pp. 299-307. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00885.x
El Amari, E Boffi; Combescure, C; Yerly, S; Calmy, A; Kaiser, L; Hasse, B; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, Hh; Bernasconi, E; Hirschel, B; Swiss HIV Cohort Study, (2011). Clinical relevance of cytomegalovirus viraemia(*,†). HIV medicine, 12(7), pp. 394-402. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00900.x
Bucher, HC; Richter, W; Glass, TR; Magenta, L; Wang, Q; Cavassini, M; Vernazza, P; Hirschel, B; Weber, R; Furrer, H; Battegay, M; Bernasconi, E (2011). Small dense lipoproteins, apolipoprotein B and risk of coronary events in HIV-infected patients on antiretroviral therapy. Journal of acquired immune deficiency syndromes JAIDS, 60(2), pp. 135-142. Philadelphia, Pa.: Lippincott Williams & Wilkins 10.1097/QAI.0b013e31824476e1
Bellini, C; Keiser, O; Chave, J-P; Evison, Jm; Fehr, J; Kaiser, L; Weber, R; Vernazza, P; Bernasconi, E; Telenti, A; Cavassini, M (2009). Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV medicine, 10(1), pp. 12-18. Oxford: Blackwell Science 10.1111/j.1468-1293.2008.00646.x
Weber, R; Huber, M; Rickenbach, M; Furrer, H; Elzi, L; Hirschel, B; Cavassini, M; Bernasconi, E; Schmid, P; Ledergerber, B (2009). Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV medicine, 10(7), pp. 407-16. Oxford: Blackwell Science 10.1111/j.1468-1293.2009.00701.x
Combescure, Christophe; Vallier, N; Ledergerber, B; Cavassini, M; Furrer, H; Rauch, A; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B (2009). How reliable is an undetectable viral load? HIV medicine, 10(8), pp. 470-6. Oxford: Blackwell Science 10.1111/j.1468-1293.2009.00714.x
Wunder, D M; Fux, C A; Bersinger, N A; Mueller, N J; Hirschel, B; Cavassini, M; Elzi, L; Schmid, P; Bernasconi, E; Mueller, B; Furrer, H (2008). Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study. HIV medicine, 9(6), pp. 427-32. Oxford: Blackwell Science 10.1111/j.1468-1293.2008.00578.x
Wolbers, M; Bucher, H C; Furrer, H; Rickenbach, M; Cavassini, M; Weber, R; Schmid, P; Bernasconi, E; Hirschel, B; Battegay, M (2008). Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV medicine, 9(6), pp. 397-405. Oxford: Blackwell Science 10.1111/j.1468-1293.2008.00566.x
Nguyen, A; Calmy, A; Schiffer, V; Bernasconi, E; Battegay, M; Opravil, M; Evison, J-M; Tarr, P E; Schmid, P; Perneger, T; Hirschel, B (2008). Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV medicine, 9(3), pp. 142-50. Oxford: Blackwell Science 10.1111/j.1468-1293.2007.00537.x
Elzi, L; Schlegel, M; Weber, R; Hirschel, B; Cavassini, M; Schmid, P; Bernasconi, E; Rickenbach, M; Furrer, H; Swiss, HIV Cohort Study (2007). Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clinical infectious diseases, 44(1), pp. 94-102. Cary, N.C.: The University of Chicago Press 10.1086/510080
Sterne, JA; May, M; Bucher, HC; Ledergerber, B; Furrer, H; Cavassini, M; Bernasconi, E; Hirschel, B; Egger, M; Swiss, HIV Cohort (2007). HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. Journal of internal medicine, 261(3), pp. 255-67. Oxford: Blackwell Scientific Publications 10.1111/j.1365-2796.2006.01761.x
Ledergerber, B; Furrer, H; Rickenbach, M; Lehmann, R; Elzi, L; Hirschel, B; Cavassini, M; Bernasconi, E; Schmid, P; Egger, M; Weber, R; Swiss, HIV Cohort Study (2007). Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clinical infectious diseases, 45(1), pp. 111-9. Cary, N.C.: The University of Chicago Press 10.1086/518619
Fux, CA; Simcock, M; Wolbers, M; Bucher, HC; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H; Swiss, HIV Cohort Study (2007). Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral therapy, 12(8), pp. 1165-73. London: International Medical Press
Wolbers, M; Opravil, M; von Wyl, V; Hirschel, B; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M; Yerly, S; Günthard, H; Bucher, HC; Swiss, HIV Cohort Study (2007). Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS, 21(16), pp. 2201-7. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/QAD.0b013e3282efacb1
Simcock, M; Blasko, M; Karrer, U; Bertisch, B; Pless, M; Blumer, L; Vora, S; Robinson, JO; Bernasconi, E; Terziroli, B; Moirandat-Rytz, S; Furrer, H; Hirschel, B; Vernazza, P; Sendi, P; Rickenbach, M; Bucher, HC; Battegay, M; Koller, MT and Swiss, HIV Cohort Study (2007). Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antiviral therapy, 12(6), pp. 931-9. London: International Medical Press
Wolbers, M; Battegay, M; Hirschel, B; Furrer, H; Cavassini, M; Hasse, B; Vernazza, PL; Bernasconi, E; Kaufmann, G; Bucher, HC; Swiss, HIV Cohort Study (2007). CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antiviral therapy, 12(6), pp. 889-97. London: International Medical Press
von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Furrer, H; Telenti, A; Hirschel, B; Vernazza, PL; Bernasconi, E; Rickenbach, M; Perrin, L; Ledergerber, B; Günthard, HF; for, the Swiss HIV Cohort Study (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of internal medicine, 167(16), pp. 1782-90. Chicago, Ill.: American Medical Association 10.1001/archinte.167.16.1782
Arnedo, M; Taffé, P; Sahli, R; Furrer, H; Hirschel, B; Elzi, L; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Bergmann, S; Beckmann, JS; Telenti, A; Tarr, PE; Swiss, HIV Cohort Study (2007). Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenetics and genomics, 17(9), pp. 755-64. London: Lippincott Williams & Wilkins 10.1097/FPC.0b013e32814db8b7
Glass, TR; Weber, R; Vernazza, PL; Rickenbach, M; Furrer, H; Bernasconi, E; Cavassini, M; Hirschel, B; Battegay, M; Bucher, HC; Swiss, HIV Cohort Study (2007). Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. HIV clinical trials, 8(2), pp. 77-85. St. Louis, Mo.: Thomas Land Publishers 10.1310/hct0802-77
Wunder, DM; Bersinger, NA; Fux, CA; Mueller, NJ; Hirschel, B; Cavassini, M; Elzi, L; Schmid, P; Bernasconi, E; Mueller, B; Furrer, H; HIV Cohort Study, Swiss (2007). Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antiviral therapy, 12(2), pp. 261-5. London: International Medical Press
Glass, TR; Ungsedhapand, C; Wolbers, M; Weber, R; Vernazza, PL; Rickenbach, M; Furrer, H; Bernasconi, E; Cavassini, M; Hirschel, B; Battegay, M; Bucher, HC; Swiss, HIV Cohort Study (2006). Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV medicine, 7(6), pp. 404-10. Oxford: Blackwell Science 10.1111/j.1468-1293.2006.00400.x
Ananworanich, J; Gayet-Ageron, A; Le Braz, M; Prasithsirikul, W; Chetchotisakd, P; Kiertiburanakul, S; Munsakul, W; Raksakulkarn, P; Tansuphasawasdikul, S; Sirivichayakul, S; Cavassini, M; Karrer, U; Genné, D; Nüesch, R; Vernazza, P; Bernasconi, E; Leduc, D; Satchell, C; Yerly, S; Perrin, L; ... (2006). CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet, 368(9534), pp. 459-65. London: Elsevier 10.1016/S0140-6736(06)69153-8
Bertschy, S; Opravil, M; Cavassini, M; Bernasconi, E; Schiffer, V; Schmid, P; Flepp, M; Chave, JP; Christen, A; Furrer, H; Swiss, HIV Cohort Study (2006). Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy. Clinical microbiology and infection, 12(7), pp. 666-71. Oxford: Blackwell Publishing 10.1111/j.1469-0691.2006.01459.x
Zinkernagel, AS; von Wyl, V; Ledergerber, B; Rickenbach, M; Furrer, H; Battegay, M; Hirschel, B; Tarr, PE; Opravil, M; Bernasconi, E; Schmid, P; Weber, R; Swiss, HIV Cohort Study (2006). Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral therapy, 11(2), pp. 131-42. London: International Medical Press
Müller, V; Ledergerber, B; Perrin, L; Klimkait, T; Furrer, H; Telenti, A; Bernasconi, E; Vernazza, P; Günthard, HF; Bonhoeffer, S; Swiss, HIV Cohort Study (2006). Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS, 20(6), pp. 889-94. Hagerstown, Md.: Lippincott Williams & Wilkins
Schüpbach, J; Günthard, H; Joos, B; Fischer, M; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B; Swiss, HIV Cohort Study (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes JAIDS, 40(3), pp. 250-6. Philadelphia, Pa.: Lippincott Williams & Wilkins
Wunder, D; Bersinger, NA; Fux, C; Weber, R; Bernasconi, E; Cavassini, M; Bucher, HC; Schiffer, V; Schmid, P; Furrer, H; Swiss, HIV Cohort Study (2005). Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. AIDS, 19(16), pp. 1837-42. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.aids.0000189852.21441.2a
Rotger, M; Taffe, P; Bleiber, G; Gunthard, HF; Furrer, H; Vernazza, P; Drechsler, H; Bernasconi, E; Rickenbach, M; Telenti, A; Swiss, HIV Cohort Study (2005). Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. Journal of infectious diseases, 192(8), pp. 1381-6. Cary, N.C.: The University of Chicago Press 10.1086/466531
Young, J; Weber, R; Rickenbach, M; Furrer, H; Bernasconi, E; Hirschel, B; Tarr, PE; Vernazza, P; Battegay, M; Bucher, HC (2005). Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antiviral therapy, 10(5), pp. 585-91. London: International Medical Press
Rauch, A; Rickenbach, M; Weber, R; Hirschel, B; Tarr, PE; Bucher, HC; Vernazza, P; Bernasconi, E; Zinkernagel, AS; Evison, J; Furrer, H; Swiss, HIV Cohort Study (2005). Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clinical infectious diseases, 41(3), pp. 395-402. Cary, N.C.: The University of Chicago Press 10.1086/431486
Kaufmann, GR; Furrer, H; Ledergerber, B; Perrin, L; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Rickenbach, M; Hirschel, B; Battegay, M; Swiss, HIV Cohort Study (2005). Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical infectious diseases, 41(3), pp. 361-72. Cary, N.C.: The University of Chicago Press 10.1086/431484
Tarr, PE; Taffé, P; Bleiber, G; Furrer, H; Rotger, M; Martinez, R; Hirschel, B; Battegay, M; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Rickenbach, M; Ledergerber, B; Telenti, A; Swiss, HIV Cohort Study (2005). Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. Journal of infectious diseases, 191(9), pp. 1419-26. Cary, N.C.: The University of Chicago Press 10.1086/429295
Young, J; Rickenbach, M; Weber, R; Furrer, H; Bernasconi, E; Hirschel, B; Tarr, PE; Vernazza, P; Battegay, M; Bucher, HC (2005). Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antiviral therapy, 10(1), pp. 73-81. London: International Medical Press
